UK approves Pfizer, AstraZeneca vaccines as booster doses for Covid-19

The UK's health regulator has approved Pfizer and AstraZeneca vaccines for booster doses against Covid-19, even as the country's decision on the third dose remains pending.

Photo: Shutterstock
Photo: Shutterstock
IANS London
3 min read Last Updated : Sep 10 2021 | 3:16 PM IST

The UK's health regulator has approved Pfizer and AstraZeneca vaccines for booster doses against Covid-19, even as the country's decision on the third dose remains pending.

"We know that a person's immunity may decline over time after their first vaccine course. I am pleased to confirm that the Covid-19 vaccines made by Pfizer and AstraZeneca can be used as safe and effective booster doses," said June Raine, MHRA Chief Executive of Medicines and Healthcare products Regulatory Agency (MHRA), in a statement on Thursday.

The decision follows a careful review of available data on safety and effectiveness of booster or supplementary vaccine doses by the MHRA and the independent Commission on Human Medicines (CHM), which advises the government, it added.

The MHRA also noted that it is now up to the Joint Committee on Vaccination and Immunisation (JCVI), the UK vaccine advisory body, "to advise on whether booster jabs will be given and if so, which vaccines should be used".

The JCVI is awaiting results on seven different booster vaccines, which is expected this week.

However, the JCVI has said a third dose should be offered to people with severely weakened immune systems, which make up about half a million people over the age of 12 in the UK.

Earlier this week, Ministers said the National Health Service (NHS) was ready to go if booster jabs were given the green light.

But, AstraZeneca chief Pascal Soriot warned against rushing into a nationwide rollout noting that it may put extra pressure on the country's already burdened NHS.

Writing in The Telegraph, he said that a third dose of vaccines against Covid-19 may not be needed for everyone in the UK.

Moreover, the decision to jab the entire population must be based on "real world clinical effectiveness data, not simply antibody measurements", Soriot wrote in the newspaper.

On the other hand, US pharmaceutical major Pfizer's CEO Albert Bourla had said that Covid vaccine recipients will "likely" need a third dose between six to 12 months after they're fully inoculated.

He also suggested the need for yearly vaccinations against coronavirus.

The US is also expected to soon roll out Covid booster vaccines for all its citizens, even as the World Health Organization has called for a moratorium on boosters.

The US has already started a third dose for immunocompromised people.

Other countries that started booster vaccines include Israel, Italy, France, and Russia.

--IANS

rvt/ksk/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccinePfizerAstraZeneca

First Published: Sep 10 2021 | 3:16 PM IST

Next Story